UroGen Pharma to Participate at Upcoming Investor Conferences
– Guggenheim 6th Annual
– Oppenheimer 34th Annual
Guggenheim 6th Annual
Fireside Chat:
Format: 1x1 meetings
Location:
Webcast Link: https://guggenheim.metameetings.net/events/guggenheimbiotech24/sessions/50270-urogen-pharma-ltd/webcast
Oppenheimer 34th Annual
Presentation:
Format: Virtual
Webcast Link: https://wsw.com/webcast/oppenheimer33/register.aspx?conf=oppenheimer33&page=urgn&url=https://wsw.com/webcast/oppenheimer33/urgn/2806968
A webcast from both conferences will also be available via the Investors section of UroGen’s website, www.urogen.com. A replay of the webcast will be available for approximately 90 days.
About
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201163986/en/
INVESTOR CONTACT:
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: